Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 4/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | BRAF | P15056 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3254633 | 0.78 | ABCG2 (0.43) | ABCG2RAB9AKDRNPSR1BRAF | |
| SCHEMBL9998100 | 0.73 | ABCG2 (0.45) | ABCG2RAB9AKDRNPSR1BRAF | |
| SCHEMBL3251020 | 0.73 | BRAF (0.56) | ABCG2RAB9AKDRBRAFMAPK14 | |
| SCHEMBL254896 | 0.63 | TSHR (0.59) | MAPK14NR3C1PGRARESR2 | |
| SCHEMBL19154982 | 0.62 | NPC1 (0.56) | RAB9ACYP1A2CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL31411241 | 0.62 | NPC1 (0.56) | RAB9ACYP1A2CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL10440879 | 0.62 | RAB9A (0.72) | RAB9ANPSR1CYP1A2CYP2C19MAPT | |
| SCHEMBL9546526 | 0.62 | L3MBTL1 (0.55) | ABCG2NPSR1MAPK14CYP1A2CYP2C9 | |
| SCHEMBL4078517 | 0.61 | KDR (0.61) | ABCG2RAB9AKDRBRAFMAPK14 | |
| SCHEMBL9507549 | 0.60 | MAPK1 (0.64) | RAB9ANPSR1CYP2C9CYP2C19L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049519-B9 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2049519-B1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2010-05-12 | — | — | EP | disclosed |
| US-7687508-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-30 | — | — | US | disclosed |
| EP-2049519-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Brystol-Myers Squibb Company (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20080027080-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-31 | — | — | US | disclosed |
| WO-2008014361-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027080-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR5, CXCR4, CCR7 | ABCG2 1167/4885RAB9A 2295/4885KDR 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.